Bergheim, Julia
Semaan, Alexander
Gevensleben, Heidrun
Groening, Susanne
Knoblich, Andreas
Dietrich, Jörn
Weber, Julia
Kalff, Jörg C.
Bootz, Friedrich
Kristiansen, Glen
Dietrich, Dimo http://orcid.org/0000-0001-9794-7927
Article History
Received: 16 October 2017
Revised: 19 January 2018
Accepted: 19 January 2018
First Online: 3 April 2018
Competing interests
: The University Hospital Bonn (Principal Investigator: Dimo Dietrich) receives research funding from Epigenomics AG, Berlin, Germany. The company aims to commercialize DNA methylation biomarkers (e.g.,SHOX2andSEPT9). Remaining authors declare no competing interests.